These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 7632756)
21. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Booij J; Andringa G; Rijks LJ; Vermeulen RJ; De Bruin K; Boer GJ; Janssen AG; Van Royen EA Synapse; 1997 Nov; 27(3):183-90. PubMed ID: 9329154 [TBL] [Abstract][Full Text] [Related]
22. A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence. Ryding E; Lindström M; Brådvik B; Grabowski M; Bosson P; Träskman-Bendz L; Rosén I Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1114-8. PubMed ID: 15014902 [TBL] [Abstract][Full Text] [Related]
23. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849 [TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. Bergström KA; Halldin C; Hall H; Lundkvist C; Ginovart N; Swahn CG; Farde L Eur J Nucl Med; 1997 Jun; 24(6):596-601. PubMed ID: 9169564 [TBL] [Abstract][Full Text] [Related]
25. Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Booij J; Busemann Sokole E; Stabin MG; Janssen AG; de Bruin K; van Royen EA Eur J Nucl Med; 1998 Jan; 25(1):24-30. PubMed ID: 9396871 [TBL] [Abstract][Full Text] [Related]
26. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data. Ichise M; Kim YJ; Erami SS; Ballinger JR; Vines D; Tanaka F; Lang AE J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210 [TBL] [Abstract][Full Text] [Related]
28. Simplified multidose preparation of iodine-123-beta-CIT: a marker for dopamine transporters. Zea-Ponce Y; Baldwin RM; Laruelle M; Wang S; Neumeyer JL; Innis RB J Nucl Med; 1995 Mar; 36(3):525-9. PubMed ID: 7884521 [TBL] [Abstract][Full Text] [Related]
29. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study. Oliver DW; Dormehl IC; Van der Schyf CJ; Neumeyer JL; Hugo N; Keeve R; Rossouw NT; Müller-Gärtner HW; Castagnoli N Arzneimittelforschung; 1997 Jun; 47(6):692-9. PubMed ID: 9239444 [TBL] [Abstract][Full Text] [Related]
30. [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Müller T; Farahati J; Kuhn W; Eising EG; Przuntek H; Reiners C; Coenen HH Eur Neurol; 1998; 39(1):44-8. PubMed ID: 9476723 [TBL] [Abstract][Full Text] [Related]
31. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103 [TBL] [Abstract][Full Text] [Related]
32. Lipophilic metabolite of [123I]beta-CIT in human plasma may obstruct quantitation of the dopamine transporter. Bergström KA; Halldin C; Kuikka JT; Swahn CG; Tiihonen J; Hiltunen J; Länsimies E; Farde L Synapse; 1995 Apr; 19(4):297-300. PubMed ID: 7792723 [TBL] [Abstract][Full Text] [Related]
33. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880 [TBL] [Abstract][Full Text] [Related]
34. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Ahlskog JE; Uitti RJ; O'Connor MK; Maraganore DM; Matsumoto JY; Stark KF; Turk MF; Burnett OL Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667 [TBL] [Abstract][Full Text] [Related]
35. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Innis RB; Seibyl JP; Scanley BE; Laruelle M; Abi-Dargham A; Wallace E; Baldwin RM; Zea-Ponce Y; Zoghbi S; Wang S Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11965-9. PubMed ID: 8265656 [TBL] [Abstract][Full Text] [Related]
36. 123I-beta-CIT SPECT for imaging serotonin transporters in Parkinson's disease. Barthel H; Hesse S; Sabri O J Nucl Med; 2004 May; 45(5):923-4. PubMed ID: 15136646 [No Abstract] [Full Text] [Related]
37. Comparative in vivo study of iodine-123-labeled beta-CIT and nor-beta-CIT binding to serotonin transporters in rat brain. Reneman L; Booij J; Lavalaye J; De Bruin K; De Wolff FA; Koopmans RP; Stoof JC; Den Heeten GJ Synapse; 1999 Oct; 34(1):77-80. PubMed ID: 10459174 [TBL] [Abstract][Full Text] [Related]